TABLE 1.

Patient Characteristics and Clinical Response

Patient	Age (y)/Sex	Diagnosis	Disease Sites	Prior IL-2	No. Doses	Duration of Treatment (Wk)	Highest Dose Received (mg/kg)	Response*	Response Duration (Mo)
1	31/M	Melanoma	Lung	No	5	12	9	NR	—
2	56/M	Melanoma	Lung, brain, subcutaneous	No	5	12	3	CR	26+
3	47/M	RCC	Lung, renal bed, retroperitoneum, liver	Yes	4	9	3	NR	—
4	56/M	RCC	Lung, hilum	Yes (LD)	5	12	3	PR	2
5	61/M	Melanoma	Lung, muscle	Yes	Dose escalate: 6	15	9	PR	4
6	43/M	Melanoma	Adrenal, axilla	Yes	Dose escalate: 7	18	9	NR	—
7	51/M	Melanoma	Retroperitoneum, muscle, subcutaneous	No	Dose escalate: 7	18	5	PR	5+
8	48/M	Melanoma	Retroperitoneum	Yes	Dose escalate: 9	24	9	PR	4+

^*Responses as of March 1, 2005.

CR indicates complete responder; F, female; LD, low dose; M, male; NR, nonresponder; PR, partial responder; RCC, renal cell carcinoma.